Selective androgen receptor modulators (SARMs) occupy a distinct regulatory position in Australia — neither freely available consumer products nor entirely prohibited substances. Their legal status is determined by the Therapeutic Goods Administration (TGA) scheduling framework, relevant state and territory legislation, Commonwealth import/export controls, and anti-doping regulations that apply in sports contexts.

This is an information resource only and does not constitute legal advice. Researchers should obtain independent legal advice regarding their specific circumstances and institutional requirements.

The TGA Scheduling Framework

Australia regulates therapeutic substances through a national scheduling system administered by the TGA under the Therapeutic Goods Act 1989 (Cth). Substances are assigned to schedules in the Poisons Standard (SUSMP) based on risk profile, medical utility, and requirements for professional oversight.

The schedules most relevant to research chemicals:

• Schedule 4 (Prescription Only Medicine): Substances requiring a valid prescription from a registered practitioner for supply. May only be dispensed by pharmacists with a valid prescription.
• Schedule 9 (Prohibited Substance): High abuse potential, no accepted medical use. Supply and possession prohibited except in specifically authorised research contexts.

MK-2866 and SARMs Under Schedule 4

Most SARMs with documented anabolic activity — including MK-2866 (Ostarine), LGD-4033 (Ligandrol), and RAD-140 — are listed in Schedule 4 of the SUSMP. This classification reflects their pharmacological activity as androgen receptor modulators with potential therapeutic applications under medical supervision.

Schedule 4 classification means:

• Supply: May only be legally supplied to a patient by a pharmacist pursuant to a valid prescription. Direct-to-consumer sale without prescription is prohibited regardless of stated purpose.
• Possession: Regulated differently across Australian states and territories. In some jurisdictions possession without prescription attracts civil penalty; in others it may constitute a criminal offence. Verify current state legislation for your jurisdiction.
• Research supply: Supply of Schedule 4 substances as reference compounds for in-vitro laboratory research — clearly labelled as not for human use — exists in a distinct regulatory context from the patient-prescription pathway Schedule 4 was designed to regulate.

Import Regulations

Importation of Schedule 4 substances into Australia requires an import permit issued by the TGA under the Customs (Prohibited Imports) Regulations 1956. Importing without a permit constitutes a Customs Act offence regardless of intended use — this applies at the border independently of state or territory possession law.

Sourcing from a domestic Australian supplier eliminates the import permit issue entirely. Ostarine Australia stocks all compounds domestically — products dispatched within Australia do not require import permits on the part of the receiving researcher.

Institutional Research Authorisation

Researchers within universities, hospitals, or research institutions typically operate under authorisation frameworks that provide a pathway for legitimate SARM research:

• Animal Ethics Committee (AEC) approval: Required for in-vivo research. AEC protocols specify approved substances and quantities, providing institutional authorisation for holding controlled substances.
• Research governance office: Many institutions maintain registers of controlled substances held for research in compliance with state drug legislation.

Researchers should consult their institution’s research compliance office before acquiring SARMs regardless of the application.

TGA Action on SARMs in Sports Supplements

The TGA has conducted compliance activities targeting SARMs found in products marketed as dietary or sports supplements. The TGA’s position is unambiguous: SARMs are Schedule 4 substances and may not be included in listed or registered therapeutic goods without appropriate TGA prescription medicine registration. Multiple public alerts have been issued regarding SARMs found in online supplement products — these actions confirm that the Schedule 4 framework applies regardless of how products are labelled or marketed.

WADA and Sport Integrity Australia

Separate from TGA scheduling, SARMs are prohibited under the WADA Prohibited List (S1.2 “Other Anabolic Agents”) at all times — both in-competition and out-of-competition. This prohibition covers all compounds with selective androgen receptor modulating activity, regardless of regulatory approval status.

Athletes subject to the WADA Code are prohibited from using SARMs regardless of their TGA Schedule 4 classification. A substance can be legally acquired for research purposes and simultaneously prohibited for athletes — these are parallel regulatory frameworks with distinct purposes administered by different bodies (TGA vs Sport Integrity Australia).

Legal Status Summary

Context	Status	Governing Framework
Therapeutic use (human)	Schedule 4 — prescription required	TGA / SUSMP
Consumer supplement sale	Prohibited	TGA / Therapeutic Goods Act
Import without permit	Prohibited	Customs Act / TGA
In-vitro laboratory research	Permitted under institutional frameworks	Institutional / State legislation
Competitive sport use	Prohibited at all times	WADA / Sport Integrity Australia

Practical Guidance for Researchers

1. Confirm institutional authorisation (AEC approval, research governance registration) before acquisition
2. Source domestically to avoid import permit requirements
3. Ensure products are clearly labelled for laboratory/research use only and not for human consumption
4. Maintain acquisition records (invoices, batch records) consistent with institutional controlled substance requirements
5. Consult your institution’s legal or compliance office regarding ambiguities in your specific context

Ostarine Australia supplies pharmaceutical-grade MK-2866 for in-vitro laboratory and research use only. All products are dispatched from within Australia. View available research compounds → | Read: MK-2866 Mechanism of Action →